Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MT-CO2 | P00403 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.31 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2892672 | 0.84 | MT-CO2 (0.43) | MT-CO2RORCCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2891573 | 0.83 | MT-CO2 (0.43) | MT-CO2RORCSCN2ASCN10APAX8 | |
| SCHEMBL2889310 | 0.82 | MT-CO2 (0.42) | MT-CO2RORCPAX8CYP1A2CYP3A4 | |
| SCHEMBL2890838 | 0.82 | MT-CO2 (0.49) | MT-CO2RORCPAX8 | |
| SCHEMBL2889485 | 0.82 | MT-CO2 (0.43) | MT-CO2RORCSCN2ASCN10APAX8 | |
| SCHEMBL2890768 | 0.81 | MT-CO2 (0.41) | MT-CO2RORC | |
| SCHEMBL2889186 | 0.81 | CNR1 (0.44) | MT-CO2RORCSCN2ASCN10APAX8 | |
| SCHEMBL2885431 | 0.78 | MT-CO2 (0.41) | MT-CO2RORCPAX8CYP1A2CYP2C9 | |
| SCHEMBL2889103 | 0.76 | MT-CO2 (0.41) | MT-CO2RORCSCN2ASCN10A | |
| SCHEMBL2893038 | 0.75 | KDR (0.41) | MT-CO2RORCPAX8CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415358-B2 | Pyrazine derivatives and their use as potassium channel modulators | NEUROSEARCH A/S (DK) | 2013-04-09 | — | — | US | disclosed |
| US-20100286161-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2010-11-11 | — | — | US | disclosed |
| WO-2009037247-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286161-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNQ5, KCNA5 | MT-CO2 2921/4885RORC 1230/4885SCN2A 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.